BAXTER INTERNATIONAL INC
No SEC Form 4 filings for $BAX in the last 30 days.
See all $BAX insider activity →Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.
Morningstar says 55% of US-listed stocks it covers beat FactSet earnings by at least 5% as of Aug. 11. It screened for six undervalued “earnings crushers” with 10%+ EPS beats and 5%+ revenue beats, including Albemarle, Atlassian, Baxter International, CarMax, Ionis Pharmaceuticals, and Sanofi, citing EPS, revenue, Morningstar ratings, and discounts to fair value.
Baxter International shares rose about 19% this week after the company reported a Q2 earnings beat and raised full-year guidance, according to S&P Global Market Intelligence and Baxter. Q2 sales were $2.96B, up 5% year over year, and GAAP net income rose to $135M. Baxter now expects 2025 sales growth of 3% to 4% and adjusted EPS of $1.95 to $2.15.
Over the past 7 days, alphai's AI scored 2 news stories mentioning BAX (BAXTER INTERNATIONAL INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent BAX coverage spans financial news, earnings and sector analysis.
Leadership transition at the CFO level can affect investor confidence, internal controls, and near-term guidance execution, especially after a recent outlook raise.
Outlook increases after a beat can be a tradable catalyst, though the article frames it as maintaining valuation rather than a major re-rate.
The article frames a clear earnings-and-guidance upside catalyst that likely supports near-term momentum and re-rates expectations.
Management transition risk is the main near-term factor, with potential knock-on effects for reporting continuity and investor sentiment.
Lot-level voluntary recall can be a manageable but negative safety signal, potentially affecting near-term trust and distribution.
alphai scores every news story that mentions BAX with an AI model for sentiment and relevance, and aggregates insider trades from BAXTER INTERNATIONAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.
4 min readMorningstar says 55% of US-listed stocks it covers beat FactSet earnings by at least 5% as of Aug. 11. It screened for six undervalued “earnings crushers” with 10%+ EPS beats and 5%+ revenue beats, including Albemarle, Atlassian, Baxter International, CarMax, Ionis Pharmaceuticals, and Sanofi, citing EPS, revenue, Morningstar ratings, and discounts to fair value.
7 min readBaxter International shares rose about 19% this week after the company reported a Q2 earnings beat and raised full-year guidance, according to S&P Global Market Intelligence and Baxter. Q2 sales were $2.96B, up 5% year over year, and GAAP net income rose to $135M. Baxter now expects 2025 sales growth of 3% to 4% and adjusted EPS of $1.95 to $2.15.
4 min readBAXTER INTERNATIONAL INC (BAX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K BAXTER INTERNATIONAL INC false 0000010456 0000010456 2026-07-31 2026-07-31 0000010456 bax:CommonStock1.00PerValueMember 2026-07-31 2026-07-31 0000010456 bax:GlobalNotes13Due2029Member 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2054
2 min readThe FDA announced multiple Class I recalls and alerts involving medical devices and related products. Items include certain ventilators and introducer kits, reprocessed electrophysiology and ultrasound catheters by Medline Industries, heart pump controllers by Abiomed, Boston Scientific ACCOLADE pacemakers, and dialysis catheter kits involving Arrow International and Merit Medical. These actions may affect supply and compliance for healthcare providers and investors.
4 min readTipRanks highlights analyst activity on PG, SFM, EDU, STLD and BAX. HSBC cut PG to Hold, trimming its $149 target, citing flat organic sales and weaker momentum. J.P. Morgan upgraded SFM to Buy, $103 target. Macquarie raised EDU to Hold, $56.50. Nick Cash initiated STLD Buy, $300 target. Citi upgraded BAX to Hold, $28 target, citing Q2 sales of $2.96B.
3 min readBaxter International shares rose about 19% over the week after the company reported encouraging Q2 results. Baxter posted $2.96B revenue, up 5% year over year, and GAAP net income of $135M. Adjusted EPS was $0.56. Analysts expected $2.8B revenue and $0.37 adjusted EPS. Baxter raised FY guidance to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.
3 min readUS stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.
7 min readDeutsche Bank revised its price target for Baxter International to $27 from $20 and kept a Hold rating, according to the bank. Baxter shares were reported around $26.72 in the article’s market snapshot. The change signals an updated valuation view for investors tracking analyst targets and sentiment.
1 min readBaxter International (BAX) reported Q2 FY2026 results on July 30, with worldwide sales up 5% to $2.96 billion and adjusted EPS of $0.56, helped by a $0.11 per-share IEEPA tariff refund. The company raised FY2026 guidance to 3% to 4% reported sales growth and adjusted EPS of $1.95 to $2.15. Analysts’ consensus remains Hold; TD Cowen raised its price target to $24.
5 min read
%252FBaxter%252520sign%252520on%252520the%252520building%252520in%252520Mississauga%25252C%252520Ontario_%252520Baxter%252520International%252520Inc_%252520By%252520JHVEPhoto.jpeg&w=3840&q=75)